TGFB1 and osteogenesis imperfecta: The variable responses of these molecularly distinct OI mouse models to potential therapeutic agents was evident in other studies employing therapeutic ligands like TGF-β and sclerostin neutralizing antibodies, thus further necessitating a precision medicine approach to treating OI (Grafe et al., 2016; Kozloff, 2019; Tauer et al., 2019).